Entecavir and intermittent etanercept therapy in a patient with concurrent hepatitis B virus infection and psoriasis

Acta Dermato-Venereologica

Volumn 93, Issue 3, 2013, Pages 373-374

  Babino, Graziella ^a   Esposito, Maria ^a   Mazzotta, Annamaria ^a   Chimenti, Sergio ^a   Giunta, Alessandro ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYCLOSPORIN; ENTECAVIR; ETANERCEPT; ETRETIN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN;

ABSENCE OF SIDE EFFECTS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; DISEASE SEVERITY; DRUG INTERMITTENT THERAPY; HEPATITIS B; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LIVER FUNCTION TEST; MALE; PRIORITY JOURNAL; PSORIASIS VULGARIS; REMISSION; ULTRAVIOLET B RADIATION; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; GUANINE; HEPATITIS B; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84876983825     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1477     Document Type: Letter

References (11)

1. Pathirana D, Ormerod AD, Saiag P Smith C, Spuls PI, Nast A, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23: 1-70.
2. Domm S, Cinatl J, Mrowietz U. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008; 159: 1217-1228.
3. Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumor necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004; 63: 18-24.
4. Caroll MB, Bond ML. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 2008; 38: 208-217.
5. Chung SJ, Kim JA, Park MC, Park YB, Lee SK. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol 2009; 36: 2416-2420.
6. Nosotti L, Francesconi F, Izzi S, Berardesca E, Morrone A, Bonifati C. Safety of antitumour necrosis factor-a therapy in psoriatic patients with hepatitis B virus infection. Br J Dermatol 2010; 162: 1408-1410.
7. Fotiadou C, Lazaridou E, Ioannides D. Safety of anti-tumour necrosis factor-a agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature. J Eur Acad Dermatol Venereol 2011; 25: 471-474.
8. Cassano N, Mastrandrea V, Principi M, Berardesca E, Morrone A, Bonifati C. Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease. J Biol Regul Homeost Agents 2011; 25: 285-289.
9. Prignano F, Ricceri F, Pescitelli L Zanieri F, Lotti T. Tumour necrosis factor-a antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients. Br J Dermatol 2011; 164: 645-647.
10. Kuroda T, Wada Y, Kobayashi D, Sato H, Murakami S, Nakano M, et al. Effect of etanercept and entecavir in a patient with rheumatoid arthritis who is a hepatitis B carrier: a review of the literature. Rheumatol Int 2012; 32: 1059-1063.
11. Keating GM. Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease. Drugs 2011; 71: 2511-2529.